HYPMY (Hypera) Change In Receivables : $253 Mil (TTM As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Hypera Change In Receivables?

Hypera's change in receivables for the quarter that ended in Mar. 2025 was $162 Mil. It means Hypera's Accounts Receivable declined by $162 Mil from Dec. 2024 to Mar. 2025 .

Hypera's change in receivables for the fiscal year that ended in Dec. 2024 was $88 Mil. It means Hypera's Accounts Receivable declined by $88 Mil from Dec. 2023 to Dec. 2024 .

Hypera's Accounts Receivable for the quarter that ended in Mar. 2025 was $215 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hypera's Days Sales Outstanding for the three months ended in Mar. 2025 was 104.59.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hypera's liquidation value for the three months ended in Mar. 2025 was $-1,536 Mil.

Hypera Change In Receivables Historical Data

The historical data trend for Hypera's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypera Change In Receivables Chart

Hypera Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-74.79

-91.05

-50.11

49.59

87.88

Hypera Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-7.37	-55.03	38.32	107.69	161.79

Hypera Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $253 Mil.

Hypera (OTCPK:HYPMY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hypera's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	215.166	/	187.719	*	91
=	104.59

2. In Ben Graham's calculation of liquidation value, Hypera's accounts receivable are only considered to be worth 75% of book value:

Hypera's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	302.203	-	2186.046	+	0.75 * 215.166	+	0.5 * 372.789
=	-1,536

Hypera Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hypera's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hypera Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hypera SA (OTCPK:HYPMY) » Definitions » Change In Receivables

Traded in Other Exchanges

HM6A:Germany HYPE3:Brazil

Address

Avenida Magalhaes de Castro, 4800, 240 Floor Continental Tower Building, Bairro Cidade Jardim, Sao Paulo, SP, BRA, CEP 05676-120

Website

https://www.hypermarcas.com.br

Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.